Last reviewed · How we verify
RDC Clinical Pty Ltd — Portfolio Competitive Intelligence Brief
7 marketed
0 filed
6 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Product 1 - AquaCelle Fish Oil Triglyceride | Product 1 - AquaCelle Fish Oil Triglyceride | marketed | ||||
| Product 2 - AquaCelle Fish Oil Ethyl Ester | Product 2 - AquaCelle Fish Oil Ethyl Ester | marketed | Omega-3 fatty acid supplement / Triglyceride-lowering agent | Multiple targets including PPAR-alpha, GPR120, and hepatic lipid metabolism pathways | Cardiovascular | |
| PlexoZome® Levagen® topical spray solution | PlexoZome® Levagen® topical spray solution | marketed | ||||
| Palm Oil capsule | Palm Oil capsule | marketed | ||||
| Placebo comparator - Microcrystalline cellulose | Placebo comparator - Microcrystalline cellulose | marketed | ||||
| Levagen+ | Levagen+ | marketed | Immunostimulant | Immune cell activation (non-specific) | Dermatology / Wound Care | |
| Product 3 - Standard Fish Oil Triglyceride | Product 3 - Standard Fish Oil Triglyceride | marketed | Omega-3 fatty acid supplement | Cardiovascular | ||
| Testofen | Testofen | phase 3 | Other | |||
| Maolactin | Maolactin | phase 3 | Other | |||
| Low Dose Maolactin | Low Dose Maolactin | phase 3 | macrolide antibiotic | 50S ribosomal subunit | Infectious diseases | |
| Food-Grown Magnesium | Food-Grown Magnesium | phase 3 | Mineral supplement / Nutritional product | Nutritional supplementation / General wellness | ||
| High Dose Maolactin | High Dose Maolactin | phase 3 | Immunomodulator | Infectious Diseases |
Therapeutic area mix
- Other · 2
- Cardiovascular · 2
- Infectious Diseases · 1
- Infectious diseases · 1
- Nutritional supplementation / General wellness · 1
- Obesity · 1
- Pain management; Neurology · 1
- Dermatology / Wound Care · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Mid-Atlantic LLC · 1 shared drug class
- Active Biotech AB · 1 shared drug class
- Air Force Military Medical University, China · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Bayer · 1 shared drug class
- Beijing Children's Hospital · 1 shared drug class
- ALK-Abelló A/S · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for RDC Clinical Pty Ltd:
- RDC Clinical Pty Ltd pipeline updates — RSS
- RDC Clinical Pty Ltd pipeline updates — Atom
- RDC Clinical Pty Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). RDC Clinical Pty Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rdc-clinical-pty-ltd. Accessed 2026-05-16.